Difference between revisions of "Mitotane (Lysodren)"
Jump to navigation
Jump to search
m |
m |
||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| + | *Uncertain date: Approved for the treatment of inoperable, functional or nonfunctional, [[Adrenocortical carcinoma|adrenal cortical carcinoma]]. | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
Revision as of 23:09, 21 June 2022
General information
Class/mechanism: Adrenal cytotoxic agent, suppresses adrenal cortex and the extra-adrenal metabolism of cortisol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- Uncertain date: Approved for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.
History of changes in EMA indication
- 4/28/2004: Indicated for symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
Also known as
- Generic name: o,p′-DDD
- Brand name: Lysodren